Decheng Capital LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 12, 2026, for the 2025 Q4 period, Decheng Capital LLC held in its portfolio 19 assets valued at $743,406,873 (i.e. $743.41M).

The most valuable assets in the portfolio included: CG ONCOLOGY INC ($264.55M), Nuvation Bio Inc. ($232.55M), and Upstream Bio Inc. ($85.34M).

The chart below shows the top 10 valuable assets, and the table below shows the top 19 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in Decheng Capital LLC Portfolio

CG ONCOLOGY INC

Nuvation Bio Inc.

Upstream Bio Inc.

AARDVARK THERAPEUTICS INC

Lyell Immunopharma, Inc.

NEWAMSTERDAM PHARMA CO NV

REVOLUTION MEDICINES INC(NSM)

Arcus Biosciences, Inc

Aclaris Therapeutics, Inc.

Equillium Inc.

Decheng Capital LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
CG ONCOLOGY INC	6371669	264551697	COM
Nuvation Bio Inc.	25954439	232551773	COM
Upstream Bio Inc.	3143078	85334568	COM
AARDVARK THERAPEUTICS INC	3917299	51414550	COM
Lyell Immunopharma, Inc.	692050	21301299	COM
NEWAMSTERDAM PHARMA CO NV	592057	20769360	COM
REVOLUTION MEDICINES INC(NSM)	200000	15930000	COM
Arcus Biosciences, Inc	541559	12905351	COM
Aclaris Therapeutics, Inc.	4041736	12165625	COM
Equillium Inc.	4447308	6893328	COM
BeyondSpring Inc.	3800702	6195145	SHS
CRINETICS PHARMACEUTICALS IN	92700	4315185	COM
KRYSTAL BIOTECH INC	17300	4265142	COM
Aura Biosciences, Inc.	360483	1964632	COM
Zentalis Pharmaceuticals Inc.	1323327	1786491	COM
Pyxis Oncology, Inc (formerly Apexigen)	326810	375832	COM
4D MOLECULAR THERAPEUTICS IN	44311	332333	COM
Nuvation Bio Inc.	646057	213198	WARRANTS
REZOLUTE INC	59900	141364	COM